Osteoarthritis & Cartilage –Intricacies of Imaging in Clinical Trials
A rising need for effective treatment that can both reduce pain and positively impact cartilage repair makes drug developers innovate in trial designs and use of more informative biomarkers, including imaging. This webinar will give practical insights into:
* Patient selection and appropriate use of imaging to account for comorbidities
* FDA approved imaging endpoints for disease modification claims and use of AI in increasing their sensitivity
* Novel imaging and scoring for osteoarthritis and cartilage repair clinical trials
The webinar is hosted by IAG, Image Analysis Group, experts in musculoskeletal imaging clinical research, delivering phase I-IV studies since 2007.
Two of IAG's experts Prof. Mikael Boesen and Dr. Olga Kubassova will speak for 45 min, followed by questions.
We look forward to seeing you at the webinar!
Dr. Olga Kubassova
Mathematician and computer scientist with 10+ years expertise in actively managing innovation in life science companies. Scientific interests are in quantitative imaging, development of novel efficacy methodologies, AI, Machine Learning in clinical trials.
Prof. Mikael Boesen
Mikael Boesen is currently employed as professor of radiology with focus on musculoskeletal imaging, and head of the musculoskeletal imaging and research at Copenhagen University and Bispebjerg and Frederiksberg Hospital in the Capital region of Denmark. He has 20 years hands-on international experience in clinical research in inflammatory and degenerative joint diseases and serves as a global PI and speaker as well as author of 120+ articles, 6 book chapters and 160 abstracts and he has served as supervisor of more than 20 PhD students and postdocs. He also brings together cross-therapeutic area expertise into MSK imaging from previous work in immuno-oncology and cardiac imaging and he currently spearheads implementation of artificial intelligence into radiological image analysis in Denmark, EU the US all of which he uses to helps drug developers and biotech companies to think outside the box when it comes to designing clinical trials and selecting appropriate imaging strategy within many therapeutic areas.